Navidea Biopharma (NAVB) Reports Q4 Loss of $0.03

Navidea Biopharma (NYSE: NAVB) reported Q4 EPS of ($0.03), versus ($0.02) reported last year. Revenue for the quarter came in at $395 thousand, versus $1 million reported last year.

For earnings history and earnings-related data on Navidea Biopharma (NAVB) click here.

You May Also Be Interested In

• Academy Sports and Outdoor (ASO) Tops Q2 EPS by 22c, Offers Guidance
• Signet Jewelers (SIG) Tops Q2 EPS by 47c, Misses on Revenue; Offers FY27 Guidance
• ServiceTitan, Inc. (TTAN) Misses Q2 EPS by 1c, Offers Guidance